These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12834817)

  • 81. A bioluminescent probe for NQO1 overexpressing cancer cell imaging
    Luo Y; Wang W; Zeng Y; Wang S; Guo X; Hu R; Yang G
    Analyst; 2022 Nov; 147(23):5264-5268. PubMed ID: 36330961
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Association of NQO1 Polymorphism with Multiple Myeloma Risk in Koreans.].
    Kang SH; Kim TY; Kim HY; Lee YK; Moon HW; Lee DS; Cho HI
    Korean J Lab Med; 2006 Apr; 26(2):71-6. PubMed ID: 18156703
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Research on the effects of rs1800566 C/T polymorphism of NAD(P)H quinone oxidoreductase 1 gene on cancer risk involves analysis of 43,736 cancer cases and 56,173 controls.
    Zhou H; Wan H; Zhu L; Mi Y
    Front Oncol; 2022; 12():980897. PubMed ID: 36338728
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms.
    Jaiswal AK; Bell DW; Radjendirane V; Testa JR
    Pharmacogenetics; 1999 Jun; 9(3):413-8. PubMed ID: 10471077
    [No Abstract]   [Full Text] [Related]  

  • 85. A promising redox cycle-based strategy for designing a catechol-type diphenylbutadiene as a potent prooxidative anti-melanoma agent.
    Dai F; Du YT; Zheng YL; Zhou B
    Free Radic Biol Med; 2019 Jan; 130():489-498. PubMed ID: 30458279
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PROTAC Nanoplatform with Targeted Degradation of NAD(P)H:Quinone Oxidoreductase 1 to Enhance Reactive Oxygen Species-Mediated Apoptosis.
    Zhang H; Xu X; Yan D; Ren C; Zhang J; Gu M; Wang Y; Wu P; Li Z; Kong L; Han C
    ACS Appl Mater Interfaces; 2023 Jan; ():. PubMed ID: 36657998
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Investigation of a functional quinine oxidoreductase (NQO2) polymorphism and cognitive decline.
    Payton A; Miyajima F; Ollier W; Rabbitt P; Pickles A; Weiss V; Pendleton N; Horan M
    Neurobiol Aging; 2010 Feb; 31(2):351-2. PubMed ID: 18538895
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Re: "NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis".
    Lanciotti M; Dufour C
    Am J Epidemiol; 2009 May; 169(10):1278-9; author reply 1279. PubMed ID: 19332427
    [No Abstract]   [Full Text] [Related]  

  • 89. Discovery of Natural Products Targeting NQO1 via an Approach Combining Network-Based Inference and Identification of Privileged Substructures.
    Wu Z; Wang Q; Yang H; Wang J; Li W; Liu G; Yang Y; Zhao Y; Tang Y
    J Chem Inf Model; 2021 May; 61(5):2486-2498. PubMed ID: 33955748
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Role of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Prevention, Diagnosis, and Treatment of Gastrointestinal Cancers.
    Ghorbani F; Mazidimoradi A; Biyabani A; Allahqoli L; Salehiniya H
    Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38318828
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Association Between NAD(P)H Quinone Oxidoreductase 1 (NQO1) Gene Methylation/Expression and Bleeding Incidence Among an Iranian Population Undergoing Warfarin Therapy.
    Hosseini MS; Pourgholi L; Ziaee S; Pourgholi M; Mandegary A; Boroumand M
    Indian J Hematol Blood Transfus; 2024 Jul; 40(3):517-521. PubMed ID: 39011266
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Oxidative reactions and schizophrenia: a review-discussion.
    Smythies JR
    Schizophr Res; 1997 Apr; 24(3):357-64. PubMed ID: 9134597
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model.
    Duan J; Göring HHH; Sanders AR; Moy W; Freda J; Drigalenko EI; Kos M; He D; Gejman PV;
    Transl Psychiatry; 2018 Aug; 8(1):158. PubMed ID: 30115913
    [TBL] [Abstract][Full Text] [Related]  

  • 94. NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia.
    Hori H; Ohmori O; Matsumoto C; Shinkai T; Nakamura J
    Psychiatry Res; 2003 Jun; 118(3):235-9. PubMed ID: 12834817
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.
    Pae CU; Yu HS; Kim JJ; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):495-500. PubMed ID: 15151706
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Genetic association of NAD(P)H quinone oxidoreductase (NQO1*2) polymorphism with NQO1 levels and risk of diabetic nephropathy.
    Sharma M; Mehndiratta M; Gupta S; Kalra OP; Shukla R; Gambhir JK
    Biol Chem; 2016 Aug; 397(8):725-30. PubMed ID: 27078674
    [TBL] [Abstract][Full Text] [Related]  

  • 97. No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.
    Hori H; Shinkai T; Matsumoto C; Ohmori O; Nakamura J
    Neuromolecular Med; 2006; 8(3):375-80. PubMed ID: 16775388
    [TBL] [Abstract][Full Text] [Related]  

  • 98. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
    Ross D; Kepa JK; Winski SL; Beall HD; Anwar A; Siegel D
    Chem Biol Interact; 2000 Dec; 129(1-2):77-97. PubMed ID: 11154736
    [TBL] [Abstract][Full Text] [Related]  

  • 99. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions.
    Zhu H; Li Y
    Cardiovasc Toxicol; 2012 Mar; 12(1):39-45. PubMed ID: 21818552
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.